About Us

Our Mission

Our Focus

Erinyes Therapeutics is a biologics pharmaceutical company focused on the development of antibacterial proteins to treat infectious diseases and combat antimicrobial resistance (AMR). As the world focuses on the evolution and treatment of the current COVID-19 pandemic, government entities and scientific bodies correctly predicted a viral pandemic from zoonotic origins1-2. As such, the government knew how to prevent viral spread and pharmaceutical companies relied on decades of government-funded research to develop vaccines within one year. As AMR becomes a more widespread threat to human health, government agencies and organizations are sending similar warnings on the rise of AMR and the possibility of not having resources to combat them3-4. According to the Centers for Disease Control (CDC), 2.8 million AMR infections occur annually in the U.S. resulting in over 35,000 deaths5. According to the World Health Organization (WHO), roughly 700,000 people die globally per year as a result of untreatable AMR bacterial infections6. It is increasingly clear that current small molecule antibiotics are not enough to address the world’s current and future antibiotic needs amidst future threats of pandemics from AMR microbes.


The Team

Daniel Propheter, Ph.D.

Founder, Principal Investigator, Chief Executive Officer, ad interim

  • B.S. Chemistry, Regis University 2006

  • Ph.D. Chemistry, UT Austin 2011


Josie Anne Vita Propheter, M.D.

Chief Operating Officer

  • B.S. Biology, Ateneo de Davao University

  • M.D. Davao Medical School Foundation


Lora Hooper, Ph.D.

Collaborator

Professor and Chair, Department of Immunology, UT Southwestern Medical Center

  • B.S. Biology, Rhodes College

  • Ph.D. Biochemistry, Washington University

References

1) Morse, S. S. et al. Lancet. "Prediction and prevention of the next pandemic zoonosis." 2012. 380(9857):1956-65.

2) Grange, Z.L., et al. PNAS. "Ranking the risk of animal-to-human spillover for newly discovered viruses." 2021. 118(15):e2002324118.

3) Spellberg, B. et al. Clinical Infectious Diseases. "The Epidemic of Antibiotic-Resistant Infections: A Call to Action for the Medical Community from the Infectious Diseases Society of America." 2008. 46(2):155-64.

4) Ghosh, S. et al. J. Infect Public Health. "Antimicrobial Resistance Threats in the emerging COVID-19 pandemic: Where do we stand?" 14(5):555-60.

5) Centers for Disease Control "Antibiotic Resistance Threats in the United States." 2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf

6) World Health Organization "Antibiotic Resistance." 2020. https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance